Injection Pen Market Size & Outlook, 2026-2034

Injection Pen Market Overview

The global injection pen market size is valued at USD 44.21 billion in 2025 and is projected to reach USD 85.68 billion by 2034, growing at a CAGR of 7.67% during the forecast period. The remarkable growth of the market is due to the continuous technological advancements in smart injection pens.

Key Market Trends & Insights

• North America dominated the market with a revenue share of 24% in 2025.
• Asia Pacific is anticipated to grow at the fastest CAGR of 47% during the forecast period.
• Based on type, the disposable injection pen segment grows at the fastest CAGR of 42% in 2025.
• By therapy, the diabetes segment dominated the market with a revenue share of 94%.
• Based on end user, hospitals and clinics dominated the market in 2025 with a revenue share of 21%.
• US. dominates the market, valued at USD 18.18 billion in 2025 and reaching USD 19.51 billion in 2026.

Table: U.S. Injection Pen Market Size (USD Billion)

Source: Straits Research

Market Size & Forecast

• 2025 Market Size: USD 44.21 billion
• 2034 Market Size: USD 85.68 billion
• CAGR (2026-2034): 7.67%
• Dominating Region: North America
• Fastest-Growing Region: Asia Pacific

The global injection pen market includes a wide range of devices designed to deliver medications safely, accurately, and conveniently across multiple therapeutic areas. By type, the market is segmented into disposable pens, preferred for single-use applications, ensuring hygiene and ease of use, and reusable pens, which support multiple uses through replaceable cartridges, offering cost efficiency and sustainability. By therapy, injection pens are widely used for diabetes management, growth hormone therapy, osteoporosis, fertility treatments, and obesity, along with other chronic and specialty conditions requiring precise dosing and patient-friendly administration. Based on end user, the market serves home care, hospitals and clinics, and other healthcare facilities, reflecting the growing trend toward self-administration and personalized treatment. Collectively, technological advancements such as ergonomic design, digital dose tracking, and compatibility with biologics continue to drive the expansion of the market worldwide.

Latest Market Trends

Shift from Single-Use to Reusable and Sustainable Injection Pen Designs

With increasing environmental awareness and stricter sustainability regulations, manufacturers are transitioning from traditional single-use disposable injection pens toward reusable and circular economy-based designs. As per the 2024 annual report of Novo Nordisk, the company launched the ReMed take-back scheme across several markets to collect and recycle used injection pens, and committed to developing reusable devices while reducing the plastic footprint per patient by 2026.

This transition reflected the industry’s move toward eco-friendly innovation, focusing on materials reuse, reduced medical waste, and carbon-neutral production processes. Such advancements not only addressed environmental and regulatory demands but also improved long-term affordability and alignment with global healthcare systems' sustainability goals.

Shift Towards Smart and Connected Injection Pens with Digital Dose Tracking

With the growing emphasis on treatment accuracy and patient adherence, the injection pen market is witnessing a major transition from standard mechanical pens to smart, connected devices integrated with digital dose tracking capabilities. Manufacturers introduced Bluetooth-enabled injection pens that synchronize with mobile health applications to record dosage history as well as monitor administration patterns. Such evolution reflected the shift of industry towards data-driven and patient-centric drug delivery systems, which have enhanced treatment adherence, real-time monitoring and remote healthcare support, which further allowed patients and healthcare providers to manage the chronic conditions more efficiently.

To get more insights about this report Download Free Sample Report

Injection Pen Market Driver

Integration of Temperature Controlled Storage in Pens for Biologics

The growing demand to maintain the stability and potency of temperature-sensitive biologics has contributed to the growth of the injection pen market. Otsuka Pharmaceutical highlighted in its press release the development of injection pens with built-in temperature control systems for peptide therapies, which further ensured drug integrity during storage and transport. Such factors underscored the increasing demand for advanced injection pens that enhanced patient safety, convenience, and efficient self-administration of biologics.

Market Restraint

Needle Stick Injury Risks in Injection Pens

The risk of accidental needle stick injuries remains a barrier to the widespread adoption of injection pens, despite advancements in safety features. According to the safety reports from the U.S. Centers for Disease Control and Prevention (CDC), accidental needle stick incidents continued to occur, particularly in regions with limited access to safe disposal methods. Such concerns underscored the ongoing demand for enhanced safety mechanisms and proper disposal solutions to ensure safe use of injection pens, especially in home and low-resource healthcare settings.

Market Opportunity

Expansion of Biologics and Specialty Drug Delivery via Injection Pens

The rising prevalence of chronic diseases and the growing use of biologics have created an opportunity for injection pens as patient-friendly delivery systems. Manufacturers are increasingly developing pens for therapies such as monoclonal antibodies, GLP-1 receptor agonists, and other biologics that require precise dosing at home. For example, in June 2025, Eli Lilly highlighted in its press release the launch of its new prefilled pen for a GLP-1 therapy, designed to simplify administration for patients with diabetes and obesity, while ensuring stability and dose accuracy. This trend underscored the potential for injection pens to expand access to complex therapies and improve treatment adherence.

Regional Analysis

North America led the injection pen market in 2025 with a 46.24% share, driven by its large diabetic population, advanced healthcare infrastructure, and strong regulatory support. According to the CDC, in 2025, about 38 million Americans were living with diabetes, several requiring insulin therapy for efficient management. The FDA focuses on safety, usability, and innovation in injector design, which further strengthens the region’s global market leadership.

In the U.S. market, the adoption of injection pens has been boosted by the rise of telehealth and online pharmacy platforms such as Ro, Hims, and Teladoc, which prescribe and deliver GLP-1s, testosterone, and weight management injectables directly to consumers. These direct-to-consumer models are helping to normalize the use of self-administered injectables, enhancing convenience and accessibility, and driving increased penetration of injection pen devices across the country.

Asia Pacific Market Insights

The Asia Pacific region is projected to be the fastest-growing market, registering a CAGR of 9.47% from 2026 to 2034. Growth is driven by countries such as Japan, India, and China, which attract international patients through competitive healthcare pricing.

Japan’s injection pen market is experiencing growth driven by strict pharmaceutical waste management and safety regulations. Government-mandated rules on needle safety, proper drug disposal, and contamination prevention, which further encouraged healthcare providers and patients to shift from traditional vials and syringes to tamper-proof, user-friendly pen systems. This regulatory focus not only ensured safer and more efficient medication administration but also underscored Japan’s commitment to advancing drug delivery technologies, reinforcing its position as a key innovator in the region’s market.

Regional Market share (%) in 2025

Source: Straits Research

Europe Market Insights

Europe’s injection pen market is experiencing steady growth, driven by the implementation of the Medical Device Regulation (MDR) and favourable EU reimbursement policies, which have made advanced injection pens more accessible through insurance coverage.

The growing role of community pharmacists, nurse-led clinics, and GP practice-based teams in the UK has been empowered to prescribe, train patients, and manage repeat supplies. This is driving injection pen uptake as local care points made initiation, hands-on training, and dose titration far easier and faster for patients, which further reduced clinic bottlenecks and also normalised self-injection.

Latin America Market Insights

Latin America is emerging as a key market for injection pens, driven by its growing medical tourism sector. Countries such as Mexico, Brazil, and Colombia offer more affordable treatments compared to North America and Europe, attracting international patients for therapies including weight management, fertility, and hormone treatments.

The Brazilian injection pen market is gaining momentum, fueled by strategic investments and the increasing demand for advanced self-administered therapies. To meet rising domestic demand and support international exports, Novo Nordisk announced a USD 1.09 billion investment in April 2025 to expand its Minas Gerais facility in Brazil. This expansion aimed to increase the manufacturing of GLP-1 injectables, such as semaglutide, which further supports in driving growth of the country’s market by ensuring product availability and supporting broader adoption of self-administered therapies.

Middle East and Africa Market Insights

The injection pen market in the Middle East & Africa is witnessing growth, driven largely by regulatory reforms that accelerate product approvals. Simplified certification processes for drug-device combinations, along with updated safety and labeling standards, are encouraging multinational manufacturers to introduce advanced insulin and GLP-1 pens in the region.

Egypt is emerging as a growing market for injection pens, marked by the country’s first locally manufactured insulin pens. According to Egypt’s Ministry of Health, this move reduced dependence on imports and addressed rising domestic demand. The Ministry’s spokesperson, Hossam Abdel-Ghaffar, highlighted the launch of the extended release batch of locally produced insulin “Glargine” pens, which was developed in collaboration between Eva Pharma and Eli Lilly, signalling a step forward for the nation’s market.

Type Insights

The reusable injection pen segment dominated the market in 2025, as these devices help minimize medical waste by allowing patients to replace only the drug cartridge rather than discarding the entire pen after each use.

The disposable injection pen segment is anticipated to register the fastest CAGR of 8.42%, driven by improved manufacturing and supply chain efficiency. These pens are easy to mass-produce, sterilize, and distribute, making them highly accessible.

Therapy Insights

The diabetes segment holds the largest market share of 48.94% in 2025, driven by the growing global diabetes burden and demand for regular insulin delivery. This growth is further supported by the increasing prevalence of type 1 and type 2 diabetes worldwide, which necessitates consistent and precise insulin administration.

The growth hormone segment is projected to register the fastest CAGR of 8.12% during the forecast period, due to the rising prevalence of growth hormone deficiency and related endocrine disorders, increasing awareness and early diagnosis of growth-related conditions, and the expanding adoption of recombinant human growth hormone therapies.

By Therapy Market Share (%), 2025

Source: Straits Research

End User Insights

The hospitals and clinics segment dominated the injection pen market in 2025, accounting for a 43.21% revenue share. Hospitals and clinics play a pivotal role in driving the global market, as they are primary settings for administering biologic and specialty injectable therapies that increasingly utilize pen-based delivery systems for precision and patient comfort. These facilities ensure proper storage, dose verification, and therapy titration, which are critical for maintaining the efficiency of injection pens.

The home care segment is projected to witness the fastest growth of 8.67% during the forecast timeframe. Patients increasingly use injection pens to self-administer medications for chronic conditions such as obesity and autoimmune disorders.

Competitive Landscape

The global injection pen market remains moderately consolidated with leading pharmaceutical and medical device companies maintaining dominance through extensive product portfolios, strong distribution networks, and ongoing innovation in drug delivery technologies.

Eli Lilly and Company: An emerging market player

A leading player in the diabetes and obesity treatment segment, Eli Lilly focuses on providing innovative biologic therapies through patient-friendly delivery systems.

• In June 2025, Eli Lilly launched the Mounjaro KwikPen in India, offering six dosage options for its GLP-1 receptor agonist, targeting diabetes and obesity treatment.

List of key players in Injection Pen Market

1. Novo Nordisk A/S
2. Eli Lilly and Company
3. Sanofi
4. Ypsomed Holding
5. Becton, Dickinson and Company
6. Merck KGaA
7. AstraZeneca plc
8. Owen Mumford Ltd
9. Haselmeier GmbH
10. Sun Pharma
11. Pfizer Inc.
12. Biocon
13. Lupin Ltd
14. Novartis
15. Boehringer Ingelheim
16. Medtronic
17. Gerresheimer
18. SHL Medical
19. Nemera
20. Stevanato Group
21. Others

To get more findings about this report Download Market Share

Strategic Initiatives

• June 2025: Lupin entered the GLP-1 agonist market in the U.S. with the launch of a generic Liraglutide pen, bioequivalent to Victoza, strengthening competition in diabetes injectables.
• October 2025: PharmaJet announced the expansion of its needle-free injection portfolio with the development of a suite of proprietary, needle-free, self-injector pens. This innovation aims to enhance patient comfort and safety by eliminating the demand for traditional needles, addressing common concerns such as needle phobia and the risk of needle-stick injuries.
• March 2025: Biocon Biologics received FDA approval for Kirsty(Insulin Aspart), an interchangeable biosimilar to NovoLog, marking a major step in biosimilar insulin accessibility in the U.S. through prefilled injection pens and vials.